Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000174911 | SCV000226309 | benign | not specified | 2015-05-05 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000174911 | SCV000311662 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Laboratory for Molecular Medicine, |
RCV000174911 | SCV000540478 | likely benign | not specified | 2016-03-29 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: 1.6% of total chromosomes in ExAC, 2.7% (44/1612) of Latino chromosomes |
Genetic Services Laboratory, |
RCV000174911 | SCV000597326 | likely benign | not specified | 2017-02-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000552531 | SCV000648528 | benign | Familial hemophagocytic lymphohistiocytosis 5 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000552531 | SCV001140967 | benign | Familial hemophagocytic lymphohistiocytosis 5 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002262768 | SCV002542982 | likely benign | Autoinflammatory syndrome | 2022-04-04 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003416073 | SCV004146480 | benign | not provided | 2022-11-01 | criteria provided, single submitter | clinical testing | STXBP2: BP4, BS1, BS2 |
Breakthrough Genomics, |
RCV003416073 | SCV005208093 | likely benign | not provided | criteria provided, single submitter | not provided |